Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012.
The prevalence of carbapenemase enzymes continues to increase. Among the Ambler class B enzymes is the New Delhi metallo-β-lactamase (NDM). This particular enzyme is capable of hydrolyzing nearly all β-lactam antimicrobial agents and has spread rapidly, becoming a global problem. Therapeutic treatment options for patients infected with isolates which produce this enzyme are difficult to manage, as cross-resistance to other antimicrobial classes is common. The Study for Monitoring Antimicrobial Resistance Trends (SMART) is a global surveillance study evaluating the antimicrobial susceptibilities of numerous Gram-negative bacterial species recovered from people with intra-abdominal and urinary tract infections. The Clinical and Laboratory Standards Institute methods and a molecular analysis identified 134 isolates of Enterobacteriaceae (nine species) and one Acinetobacter sp. with blaNDM genes. These isolates were collected in nine countries, and >95% of the isolates possessed the NDM-1 variant. The MIC90 values were >4 mg/liter and >8 mg/liter for ertapenem and imipenem, respectively. No tested β-lactam or β-lactamase inhibitor combination had activity against these isolates. Resistance to amikacin (79.9%) and levofloxacin (82.8%) was common. Nearly all the isolates encoded additional enzymes, including AmpC cephalosporinases and extended-spectrum β-lactamases. There is an urgent need for infection control and continued global monitoring of isolates which harbor the NDM enzyme, as evidenced by recent outbreaks.
International Health Management Associates, Inc., Schaumburg, Illinois, USA dbiedenbach@ihmainc.com.
D
D
Biedenbach
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
S
S
Bouchillon
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
M
M
Hackel
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
D
D
Hoban
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
K
K
Kazmierczak
IHMA Europe Sàrl, Epalinges, Switzerland.
S
S
Hawser
International Health Management Associates, Inc., Schaumburg, Illinois, USA.
R
R
Badal
D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology*; D064704:Levofloxacin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D064704:Levofloxacin; D000583:Amikacin; D001618:beta-Lactamases; C552864:beta-lactamase NDM-1